Virtus ETF Advisers LLC Atea Pharmaceuticals, Inc. Transaction History

Virtus ETF Advisers LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$3.0 - $3.79 $7,209 - $9,107	-2,403 Reduced 9.04%	24,183 $72,000
Q2 2023 Aug 14, 2023	BUY	$3.21 - $5.06 $11,677 - $18,408	3,638 Added 15.85%	26,586 $99,000
Q1 2023 May 15, 2023	SELL	$3.0 - $4.97 $26,442 - $43,805	-8,814 Reduced 27.75%	22,948 $76,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $70,043 - $99,349	16,102 Added 102.82%	31,762 $152,000
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $614 - $984	112 Added 0.72%	15,660 $89,000
Q2 2022 Aug 12, 2022	SELL	$5.33 - $8.18 $20,174 - $30,961	-3,785 Reduced 19.58%	15,548 $110,000
Q1 2022 May 16, 2022	SELL	$5.5 - $9.19 $6,314 - $10,550	-1,148 Reduced 5.61%	19,333 $140,000
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $88,580 - $514,969	11,549 Added 129.3%	20,481 $183,000
Q3 2021 Nov 15, 2021	SELL	$21.33 - $35.06 $9,875 - $16,232	-463 Reduced 4.93%	8,932 $313,000
Q2 2021 Aug 10, 2021	BUY	$19.22 - $59.08 $180,571 - $555,056	9,395 New	9,395 $202,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $271M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.